- With the availability of broad-based next-generation DNA and RNA sequencing methodologies, the ability to identify molecular subtypes of pancreatic adenocarcinomas has become a reality.
- Several key studies have attempted to define molecular subtypes of pancreatic cancer, with convergent as well as divergent classifications. These analyses have also revealed key driver pathways with potential therapeutic implications.
- What ultimately will be critical is a direct connection between these molecular subtypes and the clinical factors that predict for a response (or lack of response) to standard chemotherapy and emerging targeted therapies. The existing clinical data are insufficient to establish such connections.